Gabriel N. Hortobagyi, MD, on Early Breast Cancer: Final Invasive Disease–Free Analysis From the NATALEE Trial
2023 SABCS
Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the NATALEE trial, which continued to demonstrate improved invasive disease–free survival with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) over a NSAI alone in patients with hormone receptor–positive, HER2-negative early breast cancer (Abstract GS03-03).
The ASCO Post Staff
Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses recent data showing that for patients with stage I/II triple-negative breast cancer, 12 weeks of a neoadjuvant nonanthracycline chemotherapy regimen with nivolumab may be efficacious with either concurrent or lead-in nivolumab. Those with immune-enriched tumors had high pathologic complete response rates, identifying a subpopulation for whom a 12-week anthracycline-free chemotherapy regimen with nivolumab may be appropriate (Abstract LBO1-03).
The ASCO Post Staff
Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses an exploratory analysis of CheckMate 7FL which showed that patients with PD-L1–positive, high-risk, estrogen receptor–positive, HER2-negative primary breast cancer may achieve substantial pathologic complete response rates with the addition of nivolumab to neoadjuvant chemotherapy (Abstract GS01-01).
The ASCO Post Staff
Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, discusses the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients between the ages of 50 and 69 with stage I breast cancer. The regimen demonstrated a low risk of relapse in this population, with a genomic assay used in combination with classic clinical and biological features for treatment selection (Abstract GS02-08).
Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses updated phase III results from the TROPION-Breast01 study. The data showed an improvement in progression-free survival with datopotamab deruxtecan compared with investigator’s choice of chemotherapy across all subgroups of patients with inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer who have received one to two prior lines of chemotherapy (Abstract GS02-01).
The ASCO Post Staff
Eleftherios P. Mamounas, MD, of Orlando Health Cancer Institute, discusses primary outcomes from the NRG Oncology/NSABP B-51/RTOG 1304 study of locoregional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy (Abstract GS02-07).
